We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Preferable to Skin Test for TB Diagnosis

By LabMedica International staff writers
Posted on 06 Jul 2010
A highly accurate blood test for the diagnosis of tuberculosis (TB) is preferable to the Mantoux or tuberculin skin test (TST).

New guidelines published by the [U.S.] Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) indicate that a one-step blood test is far superior to the archaic TST. More...
Results of the blood test are ready within 24 hours and do not require a return visit from the patient.

Interferon Gamma Release Assays (IGRAs) are simple blood tests that accurately identify people infected with Mycobacterium tuberculosis, the causative agent of TB. Unlike the TST, where the results are open to interpretation, IGRAs are accurate, sensitive, and specific for the disease. The guidelines recommend the assay over the TST for testing persons who have received Bacille Calmette-Guerin (BCG) injections, as a vaccine or for cancer therapy. Another reason for the preference is for diagnosing TB infection for persons from groups that historically have low rates of returning to have TSTs read. IGRAs may be used in place of TST (without preference) to test recent contacts of persons with infectious TB or for periodic screening to address occupational exposure to TB.

The QuantiFERON-TB Gold Test (QFT) is an IGRA manufactured by Cellestis International Pty Ltd. (Chadstone, Australia). QFT is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application in the screening of immunosuppressed patients prior to antitumor necrosis factor-alpha therapy initiation and in patients with human immunodeficiency virus (HIV), cancer, or organ transplants offers distinct advantages over the TST.

Antonino Catanzaro, M.D., professor of medicine, University of California (UCSD; San Diego, USA), said, "These guidelines encapsulate the enormous body of clinical evidence on the performance of the QFT test and reflect the significant benefits this test is bringing to TB control worldwide." It is estimated that one person dies of TB every 17 seconds, causing nearly two million deaths annually. Multi-drug resistant TB is becoming an increasing problem worldwide.

Related Links:
[U.S.] Centers for Disease Control and Prevention
Cellestis International Pty Ltd.
University of California San Diego




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.